Article published Aug 14, 2026. Prices below use latest available snapshots.
Conviction: Medium Status: Researching
2026-07-31 tape note: BRBR $12.39 (-9.30% vs $13.66), RSI 48.8 (cooled from 64.1). 7D -4.32% (turned negative from +7.90%), 30D -7.19% (turned negative from +10.34%), 3M -27.97% (deepened from -22.12%). From the 52-week high, the gap is -77.39% (widened from -75.90%). Per the tape: trend "weak-up", regime "downtrend", no golden cross. No new fundamentals re-researched. Per the full-scan summaries (2026-07-31 close). 2026-08-08 tape note: BRBR $11.56 (-6.70% vs $12.39), RSI 41.7 (cooled from 48.8). 7D -6.70% (deepened from -4.32%), 30D -12.29% (deepened from -7.19%), 3M +12.12% (turned positive from -27.97%). From the 52-week high, the gap is -70.69% (narrowed from -77.39%). Per the tape: trend "weak-up", regime "downtrend", death cross confirmed. News not pulled for this move. Per the full-scan summaries (2026-08-07 close). 2026-08-14 tape note: BRBR $10.75 (-7.01% vs $11.56), RSI 36 (cooled from 41.7). 7D -7.01% (roughly flat from -6.70%), 30D -11.08% (moderated from -12.29%), 3M +10.94% (moderated from +12.12%). From the 52-week high, the gap is -74.45% (widened from -70.69%). Per the tape: trend "strong-down", regime "downtrend", death cross confirmed. No new fundamentals re-researched. Per the full-scan summaries (2026-08-14 close).
Editorial Note
The #1 protein shake brand in America just lost 81% of its value because retailers overstocked shelves. Meanwhile, 12% of US adults are on GLP-1 drugs that literally eat their muscle mass — and every single one gets told "drink more protein." BRBR is either a classic channel-stuffing fraud or the best contrarian entry into a decade-long secular demand shift. The answer to that question is worth 169% upside or another 50% down.
[FLAG FOR HUMAN REVIEW — maintained 2026-06-16] At $8.83, RSI 38.6, the stock remains deeply distressed — -86% from 52wk high, -52.3% on 3M. A small bounce this week (+7.65% 7D) is insufficient to lift the RSI out of weak territory. The May 29 human-review flag is still live. RSI 38.6 is approaching but not yet at the extreme oversold levels seen on May 29 (RSI 23.9). The +7.65% 7D bounce may reflect short covering or a news catalyst; do not interpret as thesis confirmation without verifying. Human review required before any new position sizing or thesis continuation.
[TAPE-VS-THESIS, 2026-07-11] Price has run to $12.48 (RSI 57.4, +40.07% 30D, back above SMA20/SMA50) — a real technical recovery from the $8.83 print — while the summary engine still tags
thesis flag: broken. Still -78.9% from 52wk high and death-cross intact, so this reads as an oversold bounce inside a broken structure, not a reversal. Human review flag stays live; do not treat the 30D pop as thesis confirmation.[TAPE-VS-THESIS, 2026-07-17] The bounce has cooled but largely held. BRBR $12.12 (-2.9% vs $12.48), RSI 53.1 (down from 57.4), 30D now +28.12% (still strong, decelerating from +40.07%). -0.9% below SMA20 (was +9.5% above) — a modest slip, not a breakdown. Still -79.49% from 52wk high, thesis flag still
brokenper the engine. Human review flag stays live; the technical bounce has stalled, not reversed. No new fundamentals re-researched.
[TAPE-VS-THESIS, 2026-07-25, Friday 2026-07-24 close] The bounce has resumed. BRBR $12.95 (+6.8% vs $12.12), RSI 59.5 (up from 53.1) — back above SMA20 (+2.1%, from -0.9% below), and now +22.4% above SMA50. 7D has flipped positive to +6.85% (from -2.88%), while 30D has moderated further to +8.73% (from +28.12% — deceleration continuing as the sharp June-July pop rolls out of the trailing window). -20.06% 3M (improved from -26.46%), -77.24% from 52wk high (improved from -79.49%). Death cross still confirmed per the engine tag, and
thesis flag: brokenis unchanged — this reads as a continuing oversold bounce inside a still-broken structure, not a reversal. Human review flag stays live; no new fundamentals re-researched.
[TAPE-VS-THESIS, 2026-07-28] The bounce has extended further. BRBR $13.66 (+5.5% vs $12.95), RSI 64.1 (up from 59.5) — now +6.7% above SMA20 (from +2.1%) and +28% above SMA50. 7D +7.9% (roughly in line with +6.85%), 30D +10.34% (roughly flat vs +8.73%), 3M -22.12% (roughly flat vs -20.06%). -75.9% from 52wk high (improved from -77.24%). Engine still tags
thesis flag: brokenand regime "downtrend" — this remains a continuing oversold bounce, now four refreshes long, inside a still-broken structure rather than a confirmed reversal. Human review flag stays live; no new Q2 FY2026 earnings data reviewed here. Per the full-scan summaries (2026-07-28 close).
The Story Right Now
BellRing Brands is in freefall, and the numbers don't sugarcoat it. Down 81% from its 2025 highs, trading at $15.01 with RSI at 36, death cross confirmed, and 53% below its 200-day moving average. The entire cultural-thesis watchlist is getting demolished — NKE -47% 1Y, HIMS -28% 1Y, LULU -37% 1Y — but BRBR is the worst performer by far at -80% 1Y. Consumer discretionary is a warzone right now.
The proximate cause: a securities class action alleging BellRing's sales growth was artificially inflated by retailer overstocking. When the CFO admitted retailers were cutting weeks of supply on hand, the stock dropped 19%. When the actual destocking hit, it cratered another 33% in a single day, wiping $2.9B of market value. Law firms are circling. Deutsche Bank cut its target to $31 from $35.
But here's the tension that makes this interesting: consumption hasn't broken. RTD protein shakes are still growing 7.4% YoY. GLP-1 drugs are creating a medically-mandated protein demand loop — 12% of US adults on these drugs lose 40% of their weight as muscle, and every doctor tells them to eat more protein. BellRing's own management says GLP-1 contributes roughly a quarter of their growth. Starbucks is selling Protein Lattes. 86% of Americans are actively adding protein to their diets.
The stock is pricing in permanent degradation of a business that's actually experiencing secular demand tailwinds. Management is buying back $97M/quarter at these levels — real money, not lip service. The question is whether the destocking was a one-time inventory correction or evidence of a deeper demand problem masked by channel stuffing. Q2 FY2026 earnings (announced April 9, date TBD) will be the truth serum.
June 16 update: At $8.83, RSI 38.6, -52.3% in 3M and -86% from 52wk high — marginally recovered from the May 29 print of $8.36 (RSI 23.9). The +7.65% 7D bounce is the first sign of life since the collapse. But RSI 38.6 is still in weak-to-neutral territory — not a confirmed reversal. The -4.64% 30D continues the pattern of ongoing distribution. Thesis remains in review; the +1.0% above SMA20 ($8.74) is the only faint constructive technical signal. Do not add position without human review and verification of Q2 FY2026 earnings.
July 11 update: At $12.48, RSI 57.4, +40.07% 30D — the bounce from the June 16 print has extended into a real move, now back above both SMA20 ($11.40) and SMA50 ($10.72). Still -78.9% from 52wk high and -17.4% on 3M, and the death cross remains intact, so the multi-month downtrend structure hasn't reversed. No new Q2 FY2026 earnings data reviewed here — this is a tape-only refresh. Human review still required before any new position.
July 17 update: At $12.12, RSI 53.1, +28.12% 30D — the bounce has cooled slightly (-2.9% vs 07/11) and price has slipped -0.9% below SMA20, a modest pullback rather than a breakdown. Still -79.49% from 52wk high, death cross intact. No new Q2 FY2026 earnings data reviewed here. Human review still required before any new position.
July 25 update (Friday July 24 close): At $12.95, RSI 59.5, +8.73% 30D — the bounce has resumed, up +6.8% vs 07/17 and back above SMA20 (+2.1%). Still -77.24% from 52wk high, death cross intact per the engine. No new Q2 FY2026 earnings data reviewed here. Human review still required before any new position.
July 28 update: At $13.66, RSI 64.1, +10.34% 30D — the bounce has extended further, up +5.5% vs 07/25 and now +6.7% above SMA20. -75.9% from 52wk high (improved from -77.24%), death cross intact per the engine tag. No new Q2 FY2026 earnings data reviewed here. Human review still required before any new position.
Quick Snapshot
| Signal | Reading |
|---|---|
| Overall | 🟡 Weak-up — RSI 48.8, -77.4% from 52wk high |
| Moat | Narrow — Premier Protein brand #1 in RTD with 22% share, distribution locked into club/FDM/eComm |
| Key insight | GLP-1 creates permanent protein demand floor, but channel stuffing allegations add execution risk layer |
Action Matrix
| Action | Level | Why |
|---|---|---|
| Current | RSI 48.8, weak-up | downtrend, -77.4% from 52wk high |
| Entry Zone | $13.00 - $15.00 | Current levels IF Q2 confirms consumption intact |
| Stop-Loss | $10.50 (-30%) | Below this = demand destruction confirmed |
| Target | $31.00 (+251%) | Deutsche Bank revised target — conservative analyst consensus |
Price Data
| Metric | Value |
|---|---|
| Price | $10.75 |
| RSI (14) | 36 |
| SMA20 | $12.35 (-13.0%) |
| SMA50 | $11.50 (-6.6%) |
| SMA200 | $18.71 (-42.6%) |
| Trend | strong-down |
| Golden cross | No |
| Regime | downtrend |
| 7D | -7.01% |
| 30D | -11.08% |
| 3M | +10.94% |
| From 52wk High | -74.45% |
Company Overview
One-Liner
America's #1 ready-to-drink protein shake company (Premier Protein), riding the GLP-1/protein-maxxing cultural wave.
Business Model
| Question | Answer |
|---|---|
| What they sell | RTD protein shakes, protein powders, nutrition bars |
| Who pays | Mass-market consumers via club stores (Costco), FDM, e-commerce |
| Revenue model | CPG product sales — high velocity, repeat purchase |
| How sticky | Brand loyalty + taste habit + medical recommendation (GLP-1 patients) |
Key Segments
| Segment | Revenue % | Growth | Notes |
|---|---|---|---|
| Premier Protein | ~85% | Core growth driver | #1 RTD protein shake, 22% market share |
| Dymatize | ~12% | Stable | Performance protein powder, gym channel |
| PowerBar | ~3% | Legacy | Declining, not a focus |
Geographic Mix
| Region | Revenue % | Notes |
|---|---|---|
| US | ~95% | Dominant domestic focus |
| International | ~5% | Early expansion |
Competitive Analysis
Industry Position
| Question | Answer |
|---|---|
| Market share | 22% RTD protein shakes (#1) |
| Market size (TAM) | $29.8B → $63.2B by 2033 (10.3% CAGR) |
| Growth rate | RTD +7.4% YoY, bars +6.8%, powder +7.2% |
| Key competitors | Fairlife (Coca-Cola), Orgain, OWYN, Quest (Simply Good Foods), Muscle Milk (PepsiCo) |
| Position | Leader in RTD, challenger in powder |
Competitive Moat
| Moat Type | Present? | Evidence |
|---|---|---|
| Network effects | 🔴 | No network effects in CPG |
| Switching costs | 🟡 | Taste/habit loyalty but low switching friction |
| Cost advantages | 🟢 | Scale in RTD manufacturing, whey procurement contracts |
| Intangible assets | 🟢 | Premier Protein brand #1, Costco shelf placement |
| Efficient scale | 🟡 | Category growing fast enough for new entrants |
Moat Assessment
Moat Width: Narrow Moat Trend: Stable (but competitive intensity increasing — Fairlife/Coca-Cola entering)
Summary:
Premier Protein owns the RTD convenience protein category with #1 share and dominant Costco placement. But Coca-Cola's Fairlife is the real threat — backed by infinite distribution muscle. BellRing's moat is brand and scale, not technology. In CPG, that's enough to survive but not enough to prevent share erosion.
Management Assessment
Leadership
| Role | Name | Since | Background | Notes |
|---|---|---|---|---|
| CEO | Darcy H. Davenport | 2019 | Post Holdings Active Nutrition → Premier Protein president. Career: Nestle, Dreyer's, Timbuk2 | Leadership transition announced Feb 2026 |
| CGO | Doug Cornille | — | Clif Bar, Nestlé, Clorox | Leads all sales and marketing |
| CFO | — | — | 20+ years public company finance, telecom + CPG | Named in class action |
| CLO | Craig Leupold | — | Altice USA SVP Law | 20+ years corporate legal |
Founder Involvement
| Question | Answer |
|---|---|
| Founder-led? | No — spun off from Post Holdings 2022 |
| Founder ownership | N/A |
| Skin in the game | Management team has 6.4 years avg tenure; CEO transitioning |
Capital Allocation
| Metric | Track Record |
|---|---|
| M&A discipline | Good — focused on core brands, no empire-building |
| Buyback timing | Good — $97M/quarter at depressed prices shows conviction |
| R&D investment | Low — CPG, innovation is flavors/formats not R&D |
| Debt management | Aggressive — negative equity, $1.18B net debt from Post spin-off structure |
Red Flags
- Securities class action — alleged artificial growth via channel stuffing
- CEO transition announced February 2026
- Negative equity (-$510M) — leveraged structure from Post spin-off
- No excessive exec compensation flagged
Financials
Key Metrics
| Metric | Q1 FY2026 | FY2025 | FY2024 | Trend |
|---|---|---|---|---|
| Revenue (quarterly) | $537M | $648M (Q4) | $556M (Q4) | 📈 Growing but decelerating |
| Revenue Growth YoY | +0.8% | +16.8%* | — | 📉 Massive deceleration |
| Gross Margin | 29.9% | 28.9% (Q4) | 36.9% (Q4 FY24) | 📉 Whey cost pressure |
| Operating Margin | 14.6% | 15.8% (Q4) | 20.2% (Q4 FY24) | 📉 Compression |
| FCF Margin | -1.4% | — | — | 📉 Negative in latest Q |
| Net Debt | $1.18B (gross long-term debt; ~$1.15B net of the $33M cash balance) | — | — | ➡️ Stable but high |
*FY2025 full year: $2.32B revenue, up from $1.67B in FY2023
Quality Checks
| Check | Status | Notes |
|---|---|---|
| FCF positive? | 🔴 | Negative in Q1 FY2026 (-$7.3M) — seasonal; historically positive |
| Profitable? | 🟢 | Net income $43.7M in latest Q |
| Debt manageable? | 🟡 | $1.18B net debt, negative equity, but strong EBITDA covers interest |
| Cash runway | ∞ | Profitable business, just leveraged |
Revenue Quality
| Factor | Assessment |
|---|---|
| Recurring % | High — repeat purchase CPG (protein shakes consumed daily) |
| Customer concentration | High — Costco/club stores dominate |
| Contract length | Short — CPG shelf agreements, renegotiated annually |
| Volume drivers | GLP-1 adoption, protein-maxxing trend, consumer health awareness |
Leading Indicators
| Indicator | Value | Signal |
|---|---|---|
| Revenue Acceleration | -35.5% | 🔴 Severe deceleration |
| YoY Growth | +0.8% | 🟡 Stalled |
| Earnings Beat Rate | 50% | 🟡 Neutral |
| Insider Trading | -$30.3M net (6 buys / 26 sells) | 🟡 Mixed — high sell count but management buying back shares aggressively |
| Composite | -0.3 (Neutral) | 🟡 |
Valuation
Current Multiples
| Metric | Current | Context |
|---|---|---|
| P/S | 1.07x ~0.63x (corrected 2026-08-03: the file's own ~$12.39 price × 116.3M filed shares over $2.32B TTM revenue; 1.07x was priced off a ~$21 share price this stock no longer trades at) | Historically cheap for a growth CPG name |
| EV/EBITDA | 19.4x | Stale — computed at a higher price; no on-disk EBITDA authority to recompute (noted 2026-08-03) |
| P/E | 28.8x (trailing) ~8x trailing (corrected 2026-08-03: TTM net income $183.0M on 116.3M shares ≈ $1.57 EPS at the file's own ~$12.39 price. Wave-3 note: the 28.8x traces to the April 12 origin dive, where it ALSO failed to reconcile — trailing P/E computed ~10x at that dive's own $15.01. The figure was never right; it was inherited, not merely frozen) | The multiple compressed with the price, not against it |
| Forward P/E | 26.6x | Stale — same creation-price basis; no consensus estimate on disk to recompute (noted 2026-08-03) |
Fair Value Estimate
| Method | Fair Value | Upside |
|---|---|---|
| Analyst consensus (16) | $46.88 | +431% |
| Deutsche Bank (revised down) | $31.00 | +251% |
| Acquirer's Multiple estimate | ~$30 | +240% |
| If margins normalize to 35% GM | ~$25-30 | +183-240% |
My Fair Value: $25-31 (based on normalized margins + secular demand), contingent on Q2 confirming consumption isn't broken.
Bull Case
Why This Could Work
GLP-1 creates permanent protein demand floor
- Evidence: 12% of US adults on GLP-1, 40% of weight lost = muscle, doctors prescribe protein
- Implication: Unlike cyclical food trends, this is medically mandated demand that grows with drug adoption
Destocking is one-time, not structural
- Evidence: Underlying consumption still growing 6% YoY per management; retailer inventory correction is finite
- Implication: Once shelves normalize, sales re-accelerate to match actual demand
Valuation at maximum pessimism
- Evidence: P/S 1.07x vs historical 3-5x; stock down 86% from high; analyst targets at $31-47
- Implication: Risk/reward dramatically skewed if thesis is correct — even partial recovery = 200%+ upside
Aggressive buybacks signal management conviction
- Evidence: $97M/quarter in repurchases at current levels
- Implication: Insiders putting real capital to work; they see the same secular demand data we do
Oral GLP-1 (2026) massively expands patient pool
- Evidence: Oral semaglutide removes injection barrier; market expects 2-3x patient growth
- Implication: Every new GLP-1 patient = another recurring protein buyer
Upside Scenario
| If This Happens | Stock Could |
|---|---|
| Q2 confirms consumption intact + destocking ending | $25 (183% up) in 3-6 months |
| New CEO catalyst + margin recovery + oral GLP-1 launch | $35-45 (297-410% up) in 12 months |
Bear Case
What Could Go Wrong
Channel stuffing was real, demand is overstated
- How it plays out: Consumption data was inflated; actual end-consumer demand is flat or declining
- Probability: Medium — class action suggests real concerns, not just ambulance-chasing
Fairlife/Coca-Cola takes share
- How it plays out: Coca-Cola's distribution muscle + $500M marketing budget erodes Premier Protein's #1 position
- Probability: Medium-High — Fairlife already growing faster than category
Whey protein costs stay elevated
- How it plays out: Gross margins don't recover from 30% back to 35%+; earnings disappoint
- Probability: Medium — whey is cyclical, but war/oil backdrop keeps input costs high
Debt load becomes problematic
- How it plays out: $1.18B net debt with negative equity; if earnings deteriorate further, leverage becomes toxic
- Probability: Low — EBITDA still covers interest, but worth monitoring
CEO transition goes badly
- How it plays out: Darcy Davenport leaves, new CEO changes strategy or stumbles; institutional investors sell on uncertainty
- Probability: Medium — transitions always carry risk
Thesis Killers
- Q2 FY2026 shows consumption declining (not just destocking)
- Fairlife overtakes Premier Protein as #1 RTD in tracked channels
- Debt covenant breach or credit downgrade
Downside Scenario
| If This Happens | Stock Could |
|---|---|
| Consumption actually broken + share loss to Fairlife | $5-7 (-43-21% from current) |
| Full class action settlement + margin erosion | $6-8 (-32-9% from current) |
Market-Moving News
Historical
| Date | Event | Impact | Market Reaction | Lesson |
|---|---|---|---|---|
| 2025-05 | CFO reveals retailers cutting weeks of supply | -19% | Justified — early warning | Channel inventory matters in CPG |
| 2025-08 | Destocking hits, full inventory correction | -33% in one day | Overreaction? TBD | $2.9B wiped — market priced in worst case |
| 2026-02 | Q1 FY2026 + CEO transition announced | Continued decline | Neutral-negative | New uncertainty layer |
| 2026-03 | Class action lawsuits filed (multiple firms) | Legal overhang | Ambulance-chasing or real? | Securities litigation is common after big drops |
Recent News
| Date | Headline | Source | Impact | Relevance |
|---|---|---|---|---|
| 2026-04-09 | Q2 FY2026 earnings timing announced | GlobeNewswire | 🟡 | Upcoming catalyst — the truth serum |
| 2026-03-24 | Multiple class action lawsuits filed | Multiple | 🔴 | Legal overhang, but typical post-crash ambulance chasing |
| 2026-02-03 | Q1 results + narrowed FY2026 guidance ($2.41-2.46B) | Company | 🟡 | Revenue growth stalled but not collapsing |
| 2026-02-03 | Leadership transition plan announced | Company | 🟡 | CEO Davenport transitioning — uncertainty |
News Patterns
BRBR moves on channel inventory data and competitive dynamics, not macro. The market is hyper-focused on whether consumption is real or channel-stuffed. Q2 earnings will resolve this tension one way or the other.
Related Markets & ETFs
| Symbol | Name | Relationship | 30D | Notes |
|---|---|---|---|---|
| XLP | Consumer Staples SPDR | Sector ETF | — | BRBR straddles staples/discretionary |
| XLY | Consumer Discretionary SPDR | Sector ETF | — | Broader consumer weakness |
| IWM | Russell 2000 | Small-cap index | — | BRBR now small-cap territory |
Sector Context
The entire consumer/cultural-thesis basket is getting destroyed — NKE, HIMS, LULU all in strong-down with death crosses. This is NOT BRBR-specific. Oil at $128+, war uncertainty, and consumer sentiment at lows are crushing discretionary spending. But protein shakes are closer to staples than discretionary — people drink them daily. SBUX is the only cultural-thesis name working (strong-up, golden cross), partly because it's pure staples.
Cross-References (Where This Appears in Our System)
| Location | File | Context |
|---|---|---|
| Perspective | The Protein Economy perspective | Pure-play beneficiary of GLP-1 protein demand cascade |
| Watchlists | The cultural-thesis watchlist | Tracked alongside HIMS, NKE, LULU, SBUX, CROX, DPZ |
| Active perspectives registry | — | Part of Protein Economy perspective (priority: high) |
| Community | An external analyst's GLP-1/protein-economy write-up | External analyst thesis |
Related Tickers to Monitor
| Ticker | Why Related | Suggested Placement | Priority | Notes |
|---|---|---|---|---|
| SMPL (Simply Good Foods) | Quest protein bars competitor | cultural-thesis | 🟡 | Direct comp for investor comparison |
| KO (Coca-Cola/Fairlife) | Biggest competitive threat | Already tracked | 🟢 | Monitor Fairlife share gains |
| BANB.SW (Bachem) | GLP-1 peptide manufacturer (different chain) | New watchlist? | 🟡 | Upstream of the drug, not downstream demand |
| LLY | GLP-1 drug maker — upstream catalyst | Already tracked | 🟢 | Oral GLP-1 timeline drives BRBR demand |
| NVO | GLP-1 drug maker — upstream catalyst | Already tracked | 🟢 | Semaglutide adoption rate |
| DAR (Darling Ingredients) | Creatine gummies → peptide supply chain | Research pending | 🟡 | Community-sourced cultural arbitrage signal |
Catalysts & Timing
Upcoming Catalysts
| Date | Event | Impact | Watch For |
|---|---|---|---|
| TBD (announced Apr 9) | Q2 FY2026 earnings | 🔴🟢 | Consumption data: is actual end-user demand growing or not? |
| 2026 H2 | Oral GLP-1 launches | 🟢 | Patient pool expansion = more protein buyers |
| 2026 | New CEO announcement | 🟡 | Who takes over from Davenport? |
| 2026-2027 | Whey price cycle | 🟡 | If whey deflates, gross margins recover immediately |
Key Dates
| Event | Frequency | Next Date |
|---|---|---|
| Earnings | Quarterly | TBD (Q2 FY2026, announced Apr 9) |
| Class action deadline | One-time | Lead plaintiff deadline was Mar 23, 2026 |
Entry Strategy
Position Sizing
| Conviction | Allocation |
|---|---|
| Speculative | 0% (research only) |
| Low | 1-2% |
| Medium | 3-5% |
| High | 5-10% |
My conviction: Medium (pending Q2 confirmation) Target allocation: 2-3% (starter, add on Q2 confirmation)
Entry Approach
| Strategy | Details |
|---|---|
| Entry zone | $13.00 - $15.00 (current levels or lower) |
| Starter position | 50% of target allocation now |
| Add on | Q2 earnings confirming consumption growth intact |
| Full position at | New CEO announced + whey cost inflection |
Technical Levels
| Level | Price | Notes |
|---|---|---|
| Current | $12.48 | Extended bounce off the June low |
| SMA20 | $11.40 | Price clearly above |
| Support | $8.00 | Prior low zone |
| Resistance | $13-15 | Prior entry zone; would need confirmation |
| 52-week high | ~$63 | -86% from peak |
Sources
| Type | Link | Notes |
|---|---|---|
| Tape data (price/RSI/SMA/returns) | cultural-thesis | Full-scan pre-computed summaries as of the 2026-07-31 tape |
| Investor Relations | https://bellring.com | Company website |
| Protein Economy Perspective | 2026-04-11-protein-economy | Our thesis write-up |
| Community Analysis | Community conviction doc on GLP-1 cultural shifts | External researcher's thesis |
| Class Action | Hagens Berman filing | Securities fraud allegations |
Research Log
| Date | Update |
|---|---|
| 2026-04-12 | Created deep dive — $15.01, RSI 36.3, class action + GLP-1 demand thesis |
| 2026-05-29 | BRBR $8.36, RSI 23.9, strong-down; -53.03% in 30D vs prior $15.01 — major collapse since April write-up. FLAG: prior profile was bullish at $13-15 entry zone; stock now -44% below that zone. Human review required before any new positioning. No new fundamentals re-researched. |
| 2026-06-16 | BRBR $8.83, RSI 38.6, weak-down; +5.6% since May 29 ($8.36), +7.65% 7D bounce, -4.64% 30D, -52.3% 3M, -86% from 52wkHi. RSI has partially recovered from extreme oversold (23.9→38.6) but remains weak. +1.0% above SMA20 ($8.74) is faint. Human review flag maintained. No new fundamentals re-researched. |
| 2026-07-11 | BRBR $12.48, RSI 57.4, weak-up; +41.3% since June 16 ($8.83), +40.07% 30D, -17.41% 3M, -78.88% from 52wkHi. Back above SMA20/SMA50, death cross still intact. Engine tags thesis flag: broken despite the bounce — flagged as tape-vs-thesis divergence. Human review flag maintained. No new fundamentals re-researched. |
| 2026-07-17 | BRBR $12.12, RSI 53.1, weak-up; -2.9% since 07/11, +28.12% 30D (decelerating), -26.46% 3M, -79.49% from 52wkHi. Slipped -0.9% below SMA20; death cross still intact. thesis flag: broken unchanged. Human review flag maintained. No new fundamentals re-researched. |
| 2026-07-25 | BRBR $12.95, RSI 59.5, weak-up; +6.8% since 07/17, +8.73% 30D (decelerating further), -20.06% 3M, -77.24% from 52wkHi. Reclaimed SMA20 (+2.1%); death cross still intact. thesis flag: broken unchanged. Human review flag maintained. No new fundamentals re-researched. |
| 2026-07-28 | BRBR $13.66, RSI 64.1, weak-up; +5.5% since 07/25, +10.34% 30D, -22.12% 3M, -75.9% from 52wkHi (improved). Now +6.7% above SMA20; death cross still intact. thesis flag: broken unchanged. Human review flag maintained. No new fundamentals re-researched. |
| 2026-07-31 | BRBR $12.39, RSI 48.8, weak-up; 7D -4.32%; 30D -7.19%; 3M -27.97%; -77.39% from 52wk high. No new fundamentals re-researched. |
| 2026-08-08 | BRBR $11.56, RSI 41.7, weak-up; 7D -6.70%; 30D -12.29%; 3M +12.12%; -70.69% from 52wk high. News not pulled for this move. |
The Gold
Key Discoveries
| Discovery | Implication |
|---|---|
| GLP-1 contributes ~25% of BRBR growth (management confirmed) | Not speculative — company tracks and reports this |
| $97M/quarter buybacks at $15 | Management has more conviction than the market |
| Negative equity is structural (Post spin-off), not distress | Don't confuse leverage structure with business health |
| Class action is typical ambulance-chasing post 30%+ drop | Every big drop gets lawsuits; doesn't mean fraud is proven |
| Premier Protein is #1 in RTD but Fairlife is gaining fast | Competitive moat is real but under pressure |
| 2026-08-14 | BRBR $10.75, RSI 36, strong-down; 7D -7.01%; 30D -11.08%; 3M +10.94%; -74.45% from 52wk high. No new fundamentals re-researched. |
Open Questions
- Q2 FY2026: Is end-consumer consumption actually growing, or was it all channel stuffing?
- Who replaces Darcy Davenport as CEO?
- How much market share is Fairlife (Coca-Cola) actually taking?
- When do whey protein costs inflect back down?
- Will oral GLP-1 materially expand the protein demand TAM?
- [NEW 2026-05-29, maintained 2026-06-16] What happened in Q2 FY2026 earnings? Stock is at $8.83 — the thesis-confirming print was supposed to be the catalyst. Was the thesis wrong?
- [NEW 2026-06-16] What drove the +7.65% 7D bounce? News catalyst or short covering? Verify before interpreting as trend change.
Perspective Connection
This deep dive feeds directly into the Protein Economy perspective. BRBR is the pure-play picks-and-shovels thesis — it doesn't make the GLP-1 drug, it makes what every drug user NEEDS. The thesis lives or dies on whether the demand signal is secular (cultural arbitrage says yes) or whether competitive intensity from Fairlife makes BRBR a worse picks-and-shovels play than it appears.